Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Chief Medical Officer | May 11, 2026 | May 13, 2026 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Medical Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 191,395 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Sale · Disposed 11,108 · Balance 191,395 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2036-09-30 | Direct | 135,000 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 135,000 · Balance 135,000 F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 180,000 |
Reported balance
After 2026-09-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-30 · Grant · Acquired 180,000 · Balance 180,000 F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 135,000 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Grant · Acquired 135,000 · Balance 135,000 F3: Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. F4: Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones. F5: Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
F4: Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.
F5: Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 01:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantPerformance Stock Units · Derivative | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-113342 · tm2626734-2_4seq1.xml · derivative · entry 3 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common stock · 135,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. F4 · shares: Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones. F5 · derivative.exercise_date: Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones. F5 · derivative.expiration_date: Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 01:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 180,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-113342 · tm2626734-2_4seq1.xml · derivative · entry 2 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common stock · 180,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F1 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 01:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Options (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001104659-26-113342 · tm2626734-2_4seq1.xml · derivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common stock · 135,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:16 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 11,108 | $9.94 | $110,384.64 |
DisclosureSEC source: 0001628280-26-034606 · wk-form4_1778703361.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,395 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 00:01 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 6,435 | $11.10 | $71,431.07 |
DisclosureSEC source: 0001628280-26-019950 · wk-form4_1773964912.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,503 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on March 18, 2024. The sale does not represent a discretionary trade. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:59 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001628280-26-013533 · wk-form4_1772503183.xml · derivative · entry 2 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2036-02-25 F2 · derivative.exercise_date: The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:59 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013533 · wk-form4_1772503183.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,938 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 23:12 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 5,685 | $11.89 | $67,594.65 |
DisclosureSEC source: 0001628280-26-009300 · wk-form4_1771456332.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,938 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:15 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001655759-25-000087 · wk-form4_1747170938.xml · derivative · entry 2 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2035-05-08 F2 · derivative.exercise_date: The option was granted by the Issuer on May 9, 2025, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:15 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 59,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000087 · wk-form4_1747170938.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,623 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on May 9, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 12:06 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 8,658 | $8.59 | $74,372.22 |
DisclosureSEC source: 0001655759-25-000064 · wk-form4_1742386009.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,023 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on March 18, 2024. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 84,330 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001655759-25-000023 · wk-form4_1739926672.xml · derivative · entry 2 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,330 Underlying: Common Stock · 84,330 shares Expires 2035-02-12 F2 · derivative.exercise_date: The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February 13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 55,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000023 · wk-form4_1739926672.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,681 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 20:15 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 93,879 | $0.00 Strike: $42.60 | $0.00 |
DisclosureSEC source: 0001655759-24-000040 · wk-form4_1711052087.xml · derivative · entry 2 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,879 Underlying: Common Stock · 93,879 shares Expires 2034-03-17 F2 · derivative.exercise_date: The option was granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on March 18, 2025, with the remainder of the shares vesting in equal monthly installments following March 18, 2025 through March 18, 2028. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 20:15 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 63,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000040 · wk-form4_1711052087.xml · nonDerivative · entry 1 Berkowitz Noah · CIK 0001369900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,452 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.